Citadel Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.58B Sell
1,721,100
-515,300
-23% -$522M 0.26% 55
2025
Q4
$2.4B Sell
2,236,400
-90,800
-4% -$86.8M 0.36% 40
2025
Q3
$1.78B Sell
2,327,200
-1,412,300
-38% -$1.05B 0.27% 48
2025
Q2
$2.92B Buy
3,739,500
+1,803,800
+93% +$1.4B 0.51% 27
2025
Q1
$1.6B Sell
1,935,700
-212,100
-10% -$176M 0.3% 35
2024
Q4
$1.66B Buy
2,147,800
+324,200
+18% +$268M 0.29% 35
2024
Q3
$1.62B Buy
1,823,600
+517,500
+40% +$465M 0.31% 33
2024
Q2
$1.18B Sell
1,306,100
-422,600
-24% -$338M 0.24% 46
2024
Q1
$1.34B Buy
1,728,700
+415,700
+32% +$296M 0.26% 38
2023
Q4
$765M Buy
1,313,000
+166,700
+15% +$97.3M 0.15% 65
2023
Q3
$616M Sell
1,146,300
-119,500
-9% -$61.6M 0.13% 75
2023
Q2
$594M Buy
1,265,800
+265,900
+27% +$112M 0.12% 81
2023
Q1
$343M Sell
999,900
-75,000
-7% -$25.3M 0.08% 166
2022
Q4
$393M Sell
1,074,900
-395,100
-27% -$140M 0.09% 152
2022
Q3
$475M Buy
1,470,000
+955,700
+186% +$303M 0.11% 100
2022
Q2
$167M Sell
514,300
-264,400
-34% -$79.4M 0.04% 347
2022
Q1
$223M Sell
778,700
-192,700
-20% -$49.6M 0.05% 303
2021
Q4
$268M Sell
971,400
-204,100
-17% -$51.7M 0.05% 251
2021
Q3
$272M Buy
1,175,500
+319,800
+37% +$78.9M 0.06% 244
2021
Q2
$196M Sell
855,700
-51,400
-6% -$10.3M 0.04% 322
2021
Q1
$169M Buy
907,100
+79,200
+10% +$15.5M 0.04% 349
2020
Q4
$140M Buy
827,900
+358,600
+76% +$53.5M 0.04% 393
2020
Q3
$69.5M Buy
469,300
+8,800
+2% +$1.36M 0.02% 652
2020
Q2
$75.6M Sell
460,500
-87,500
-16% -$13.4M 0.03% 542
2020
Q1
$76M Sell
548,000
-121,100
-18% -$16.6M 0.03% 452
2019
Q4
$87.9M Buy
669,100
+273,600
+69% +$31.7M 0.04% 461
2019
Q3
$44.2M Buy
395,500
+70,400
+22% +$7.84M 0.02% 829
2019
Q2
$36M Sell
325,100
-108,600
-25% -$12.8M 0.02% 941
2019
Q1
$56.3M Sell
433,700
-166,300
-28% -$20.2M 0.03% 631
2018
Q4
$69.4M Sell
600,000
-150,100
-20% -$16.8M 0.04% 470
2018
Q3
$80.5M Buy
750,100
+394,700
+111% +$39.5M 0.04% 503
2018
Q2
$30.3M Buy
355,400
+110,500
+45% +$9.08M 0.01% 985
2018
Q1
$18.9M Sell
244,900
-251,700
-51% -$20.3M 0.01% 1164
2017
Q4
$41.9M Buy
496,600
+270,900
+120% +$23M 0.03% 711
2017
Q3
$19.3M Sell
225,700
-53,700
-19% -$4.4M 0.01% 1088
2017
Q2
$23M Sell
279,400
-27,200
-9% -$2.22M 0.02% 912
2017
Q1
$25.8M Sell
306,600
-214,800
-41% -$17.2M 0.02% 801
2016
Q4
$38.3M Buy
521,400
+115,600
+28% +$8.61M 0.04% 499
2016
Q3
$32.6M Buy
405,800
+103,500
+34% +$8.28M 0.03% 601
2016
Q2
$23.8M Buy
302,300
+28,500
+10% +$2.15M 0.03% 659
2016
Q1
$19.7M Buy
273,800
+75,100
+38% +$5.68M 0.02% 753
2015
Q4
$16.7M Sell
198,700
-130,700
-40% -$10.8M 0.02% 940
2015
Q3
$27.6M Buy
329,400
+27,500
+9% +$2.32M 0.03% 704
2015
Q2
$25.2M Buy
301,900
+68,900
+30% +$5.25M 0.02% 857
2015
Q1
$16.9M Buy
233,000
+99,900
+75% +$7.11M 0.02% 1079
2014
Q4
$9.18M Sell
133,100
-700
-0.5% -$47.2K 0.01% 1459
2014
Q3
$8.68M Sell
133,800
-11,600
-8% -$734K 0.01% 1476
2014
Q2
$9.04M Sell
145,400
-45,000
-24% -$2.68M 0.01% 1352
2014
Q1
$11.2M Sell
190,400
-24,800
-12% -$1.38M 0.01% 1187
2013
Q4
$11M Sell
215,200
-35,300
-14% -$1.77M 0.01% 1154
2013
Q3
$12.6M Buy
250,500
+15,400
+7% +$806K 0.02% 968
2013
Q2
$11.5M Buy
+235,100
New +$12.8M 0.02% 979

Other funds holding LLY

Citadel Advisors's LLY Position: Q1 2026 in Review

Citadel Advisors reduced its Eli Lilly (LLY) stake by 65% in Q1 2026, selling an estimated $464M and leaving 241,714 shares worth $222M. The position accounts for 0.04% of the portfolio, ranked #410.

Citadel Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $880M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Citadel Advisors held 241,714 shares of Eli Lilly worth $222M as of Q1 2026.
  • Citadel Advisors sold 458,045 Eli Lilly shares in Q1 2026, an estimated $464M.
  • Eli Lilly made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #410 holding.
  • Citadel Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Eli Lilly position peaked at $880M in Q3 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.